JP2012500004A5 - - Google Patents

Download PDF

Info

Publication number
JP2012500004A5
JP2012500004A5 JP2011523086A JP2011523086A JP2012500004A5 JP 2012500004 A5 JP2012500004 A5 JP 2012500004A5 JP 2011523086 A JP2011523086 A JP 2011523086A JP 2011523086 A JP2011523086 A JP 2011523086A JP 2012500004 A5 JP2012500004 A5 JP 2012500004A5
Authority
JP
Japan
Prior art keywords
subject
absence
risk
determined
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011523086A
Other languages
English (en)
Other versions
JP2012500004A (ja
JP5833922B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/053373 external-priority patent/WO2010019550A2/en
Publication of JP2012500004A publication Critical patent/JP2012500004A/ja
Publication of JP2012500004A5 publication Critical patent/JP2012500004A5/ja
Application granted granted Critical
Publication of JP5833922B2 publication Critical patent/JP5833922B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Description

幾つかの実施の形態では、前記遺伝的変異が存在しない又は存在する被験体と比較して、該遺伝的変異の存在又は非存在により該被験体の危険性が増大していることが決定された場合、より低年齢（例えばＡｐｏＥ ４／４被験体では、５５歳以上で始めるのではなく、４５歳、４６歳、４７歳、４８歳、４９歳、５０歳、５１歳、５２歳又は５３歳で始め、その後毎年連続的に投与し；ＡｐｏＥ ４／３被験体では、６０歳以上で始めるのではなく、５０歳、５１歳、５２歳、５３歳、５４歳、５５歳、５６歳、５７歳又は５８歳で始め、その後毎年連続的に投与し；ＡｐｏＥ ３／３被験体では、６５歳以上で始めるのではなく、５５歳、５６歳、５７歳、５８歳、５９歳、６０歳、６１歳、６２歳又は６３歳で始め、その後毎年連続的に投与し；ＡｐｏＥ ２／３被験体では、７０歳以上で始めるのではなく、６０歳、６１歳、６２歳、６３歳、６４歳、６５歳、６６歳、６７歳又は６８歳で始め、その後毎年連続的に投与する）で該被験体において前記投与する工程を行う。

Claims (2)

  1. 前記遺伝的変異が存在しない又は存在する被験体と比較して、該遺伝的変異の存在又は非存在により該被験体の危険性が増大していることが決定された場合、より低年齢で該被験体に投与するための前記活性剤が調製される工程を行う、請求項４に記載の方法。
  2. 前記遺伝的変異が存在しない又は存在する被験体と比較して、該遺伝的変異の存在又は非存在により該被験体の危険性が増大していることが決定された場合、より低年齢で該被験体に投与するための前記活性剤が調製される工程を行う、請求項４５に記載の方法。
JP2011523086A 2008-08-12 2009-08-11 疾患危険因子を同定する方法 Active JP5833922B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US8820308P 2008-08-12 2008-08-12
US61/088,203 2008-08-12
US18667309P 2009-06-12 2009-06-12
US61/186,673 2009-06-12
US22464709P 2009-07-10 2009-07-10
US61/224,647 2009-07-10
PCT/US2009/053373 WO2010019550A2 (en) 2008-08-12 2009-08-11 Method of identifying disease risk factors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015212976A Division JP2016047058A (ja) 2008-08-12 2015-10-29 疾患危険因子を同定する方法

Publications (3)

Publication Number Publication Date
JP2012500004A JP2012500004A (ja) 2012-01-05
JP2012500004A5 true JP2012500004A5 (ja) 2012-10-04
JP5833922B2 JP5833922B2 (ja) 2015-12-16

Family

ID=41669605

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2011523086A Active JP5833922B2 (ja) 2008-08-12 2009-08-11 疾患危険因子を同定する方法
JP2015212976A Pending JP2016047058A (ja) 2008-08-12 2015-10-29 疾患危険因子を同定する方法
JP2017217336A Pending JP2018075005A (ja) 2008-08-12 2017-11-10 疾患危険因子を同定する方法
JP2018228465A Active JP6815372B2 (ja) 2008-08-12 2018-12-05 疾患危険因子を同定する方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2015212976A Pending JP2016047058A (ja) 2008-08-12 2015-10-29 疾患危険因子を同定する方法
JP2017217336A Pending JP2018075005A (ja) 2008-08-12 2017-11-10 疾患危険因子を同定する方法
JP2018228465A Active JP6815372B2 (ja) 2008-08-12 2018-12-05 疾患危険因子を同定する方法

Country Status (32)

Country Link
US (4) US8815508B2 (ja)
EP (2) EP2324126B1 (ja)
JP (4) JP5833922B2 (ja)
KR (3) KR20180053432A (ja)
CN (3) CN102177436B (ja)
AU (3) AU2009282114B2 (ja)
BR (1) BRPI0917948A2 (ja)
CA (1) CA2735578C (ja)
CL (1) CL2011000298A1 (ja)
CO (1) CO6351823A2 (ja)
CY (1) CY1115412T1 (ja)
DK (1) DK2324126T3 (ja)
DO (1) DOP2011000052A (ja)
EA (1) EA021399B1 (ja)
ES (1) ES2463766T3 (ja)
GE (1) GEP20146107B (ja)
HK (1) HK1153511A1 (ja)
HR (1) HRP20140709T1 (ja)
IL (2) IL211140A (ja)
MA (1) MA32619B1 (ja)
ME (1) ME01898B (ja)
MX (1) MX2011001671A (ja)
NZ (3) NZ591107A (ja)
PE (3) PE20110565A1 (ja)
PL (1) PL2324126T3 (ja)
PT (1) PT2324126E (ja)
RS (1) RS53383B (ja)
SG (1) SG193793A1 (ja)
SI (1) SI2324126T1 (ja)
SM (1) SMT201400088B (ja)
WO (1) WO2010019550A2 (ja)
ZA (1) ZA201101095B (ja)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA021399B1 (ru) * 2008-08-12 2015-06-30 Зинфандел Фармасьютикалз, Инк. Способ идентификации факторов риска заболеваний
US8846315B2 (en) * 2008-08-12 2014-09-30 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
KR101952965B1 (ko) 2010-05-25 2019-02-27 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Ｂａｍｂａｍ：고처리율 서열분석 데이터의 병렬 비교 분석
US9646134B2 (en) * 2010-05-25 2017-05-09 The Regents Of The University Of California Bambam: parallel comparative analysis of high-throughput sequencing data
AU2011354696B2 (en) * 2011-01-10 2015-03-05 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
KR20180050420A (ko) 2011-01-10 2018-05-14 진판델 파마슈티컬스 인코포레이티드 알츠하이머 병 치료를 위한 방법 및 약품
AU2013204020B2 (en) * 2011-01-10 2016-03-31 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
US20120231457A1 (en) * 2011-03-10 2012-09-13 Nikolaos Tezapsidis Compositions and methods for assessing a genetic risk of developing late-onset alzheimer's disease (load)
US8718950B2 (en) 2011-07-08 2014-05-06 The Medical College Of Wisconsin, Inc. Methods and apparatus for identification of disease associated mutations
US20130080182A1 (en) * 2011-09-26 2013-03-28 Athleticode Inc. Methods For Using DNA Testing To Screen For Genotypes Relevant To Athleticism, Health And Risk Of Injury
JP2015505314A (ja) * 2012-01-09 2015-02-19 武田薬品工業株式会社 アルツハイマー病を治療する方法及び医薬品
GB201209689D0 (en) * 2012-05-31 2012-07-18 Imp Innovations Ltd Methods
US10586612B2 (en) 2013-03-01 2020-03-10 Actx, Inc. Cloud-like medical-information service
JPWO2015174544A1 (ja) * 2014-05-16 2017-04-20 国立研究開発法人国立精神・神経医療研究センター 精神疾患判定マーカー
WO2017015543A1 (en) 2015-07-23 2017-01-26 Asuragen, Inc. Methods, compositions, kits, and uses for analysis of nucleic acids comprising repeating a/t-rich segments
JP7475811B2 (ja) * 2016-05-20 2024-04-30 シーダーズ―シナイ メディカル センター 遺伝子に基づく炎症性腸疾患の診断
CN105969885A (zh) * 2016-06-24 2016-09-28 江苏雄鸣医药科技有限公司 一种阿尔兹海默症的基因诊断试剂盒
WO2018132755A1 (en) * 2017-01-12 2018-07-19 Duke University Compositions and methods for disrupting the molecular mechanisms associated with mitochondrial dysfunction and neurodegenerative disease
WO2018175581A1 (en) * 2017-03-21 2018-09-27 The Jackson Laboratory A GENETICALLY MODIFIED MOUSE EXPRESSING HUMAN APOE4 MOUSE Trem2.p.R47H AND METHODS OF USE THEREOF
CA3071626A1 (en) * 2017-07-31 2019-02-07 Quest Diagnostics Investments Llc Apolipoprotein e isotype detection by mass spectrometry
WO2019086555A1 (en) * 2017-10-31 2019-05-09 Ge Healthcare Limited Medical system for diagnosing cognitive disease pathology and/or outcome
US20200357523A1 (en) * 2018-01-31 2020-11-12 Curelator, Inc. Early Feedback of Disease Factors to Improve Patient Quality of Life, Engagement and Persistence
KR102303638B1 (ko) * 2018-04-13 2021-09-23 사회복지법인 삼성생명공익재단 알츠하이머성 치매가 발병될 가능성 평가방법
US20210230696A1 (en) 2018-05-07 2021-07-29 Biotx.Ai Gmbh Method for predicting the risk of late-onset alzheimer's diseases
CA3100897A1 (en) * 2018-05-18 2019-11-21 Anavex Life Sciences Corp. Optimized sigma-1 agonist method of responder selection and treatment
EP3626835A1 (en) * 2018-09-18 2020-03-25 Sistemas Genómicos, S.L. Method for genotypically identifying both alleles of at least one locus of a subject's hla gene
KR102127903B1 (ko) * 2019-01-29 2020-06-29 연세대학교 산학협력단 염증성 호흡기 질환의 진단용 바이오마커
CA3141888A1 (en) * 2019-05-30 2020-12-03 The University Of Newcastle A method of treatment or prophylaxis
CN111187825A (zh) * 2020-01-15 2020-05-22 丁玎 阿尔兹海默症的tomm40基因及apoe基因的易感位点的检测方法及试剂盒
CN111593107A (zh) * 2020-01-15 2020-08-28 丁玎 阿尔兹海默症易感位点rs10119与rs71352238的检测方法及试剂盒
KR102535235B1 (ko) * 2020-11-25 2023-05-26 서울대학교산학협력단 알츠하이머병 발병 위험도 예측을 위한 단일염기다형성 마커 및 이의 용도
RU2757522C1 (ru) * 2021-06-02 2021-10-18 Федеральное Государственное Бюджетное Учреждение "Национальный Медицинский Исследовательский Центр Эндокринологии" Министерства Здравоохранения Российской Федерации (Фгбу "Нмиц Эндокринологии" Минздрава России) СПОСОБ ПРОГНОЗИРОВАНИЯ РАЗВИТИЯ ХРОНИЧЕСКОЙ БОЛЕЗНИ ПОЧЕК У ПАЦИЕНТОВ С САХАРНЫМ ДИАБЕТОМ 1 и 2 ТИПА (варианты)
KR20230150497A (ko) * 2022-04-22 2023-10-31 사회복지법인 삼성생명공익재단 유럽-동아시아인 데이터 기반 알츠하이머병 치매의 발병 위험군 또는 조기 증상 발현 위험군, 기억상실형 경도인지장애의 발병 위험군 및/또는 아밀로이드β 침착에 대한 PET 양성 위험군을 예측하기 위한 정보를 제공하는 방법

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US663780A (en) * 1898-09-09 1900-12-11 Wheeler & Wilson Mfg Co Trimming attachment for sewing-machines.
US4302204A (en) 1979-07-02 1981-11-24 The Board Of Trustees Of Leland Stanford Junior University Transfer and detection of nucleic acids
US4358535A (en) 1980-12-08 1982-11-09 Board Of Regents Of The University Of Washington Specific DNA probes in diagnostic microbiology
FI63596C (fi) 1981-10-16 1983-07-11 Orion Yhtymae Oy Mikrobdiagnostiskt foerfarande som grundar sig pao skiktshybridisering av nukleinsyror och vid foerfarandet anvaenda kombinationer av reagenser
US4994373A (en) 1983-01-27 1991-02-19 Enzo Biochem, Inc. Method and structures employing chemically-labelled polynucleotide probes
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
US6060237A (en) * 1985-02-26 2000-05-09 Biostar, Inc. Devices and methods for optical detection of nucleic acid hybridization
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US5112460A (en) * 1986-10-21 1992-05-12 Northeastern University High performance microcapillary gel electrophoresis
ATE186724T1 (de) 1987-09-04 1999-12-15 Beecham Group Plc Substituierte thiazolidindionderivate
US5595883A (en) * 1990-06-01 1997-01-21 E. R. Squibb & Sons, Inc. Method of diagnosing alzheimer's disease by measuring acetylcholinesterase activity in ocular fluid
US5171750A (en) 1991-09-26 1992-12-15 The United States Of America As Represented By The Department Of Health And Human Services Substituted phenserines as specific inhibitors of acetylcholinesterase
TW263504B (ja) 1991-10-03 1995-11-21 Pfizer
US5326770A (en) * 1992-07-17 1994-07-05 The Du Pont Merck Pharmaceutical Company Monoamine oxidase-B (MAO-B) inhibitory 5-substituted 2,4-thiazolidinediones useful in treating memory disorders of mammals
NZ248573A (en) * 1992-09-10 1996-02-27 Lilly Co Eli 5-arylmethyl (and methylidene) thiazolidin-4-one derivatives; their preparation and pharmaceutical compositions
EP0625212B1 (en) 1992-10-13 2004-03-24 Duke University Methods of detecting alzheimer's disease
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
ES2100129B1 (es) 1995-10-11 1998-02-16 Medichem Sa Nuevos compuestos aminopiridinicos policiclicos inhibidores de acetilcolinesterasa, procedimiento para su preparacion y su utilizacion.
JPH09176162A (ja) 1995-12-22 1997-07-08 Toubishi Yakuhin Kogyo Kk チアゾリジンジオン誘導体及びその製造法並びにそれを含む医薬組成物
US6128587A (en) 1997-01-14 2000-10-03 The Regents Of The University Of California Method and apparatus using Bayesian subfamily identification for sequence analysis
US5904824A (en) * 1997-03-07 1999-05-18 Beckman Instruments, Inc. Microfluidic electrophoresis device
JP2001514663A (ja) * 1997-03-12 2001-09-11 エスモンド，ロバート ダブリュー． アルツハイマー病を処置または予防するための方法
DE69809827D1 (de) 1997-03-31 2003-01-16 Korea Res Inst Chem Tech Chinolinische Sulfid-Derivate als NMDA Rezeptor-Antagonisten und Verfahren zu ihrer Herstellung
DE69834508T2 (de) * 1997-11-19 2006-11-23 Takeda Pharmaceutical Co. Ltd. Apoptoseinhibitoren
US6964868B1 (en) 1998-01-28 2005-11-15 Nuvelo, Inc. Human genes and gene expression products II
US7122373B1 (en) 1998-05-14 2006-10-17 Nuvelo, Inc. Human genes and gene expression products V
US20040058873A1 (en) * 1998-03-12 2004-03-25 Esmond Robert W. Method for treating or preventing Alzheimer's disease
JP2002518022A (ja) 1998-06-16 2002-06-25 ノヴァ モレキュラー インク． Ｂｃｈｅ遺伝子型の決定による神経疾患の治療法
WO2000020634A1 (en) 1998-10-01 2000-04-13 Nova Molecular, Inc. Methods for treating or identifying a subject at risk for a neurological disease by determining the presence of a variant gpiiia and/or variant gpiib allele
US6291182B1 (en) * 1998-11-10 2001-09-18 Genset Methods, software and apparati for identifying genomic regions harboring a gene associated with a detectable trait
US6191154B1 (en) * 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
CN1078616C (zh) * 1998-12-16 2002-01-30 中国科学院上海生命科学研究中心 一种检测样品中是否存在老年痴呆病基因的方法和试剂盒
JP2000273040A (ja) * 1999-01-19 2000-10-03 Sankyo Co Ltd トログリタゾンを含有するアポトーシス抑制剤
US6401043B1 (en) 1999-04-26 2002-06-04 Variagenics, Inc. Variance scanning method for identifying gene sequence variances
WO2000066102A2 (en) 1999-04-29 2000-11-09 City Of Hope Pentoxifylline, pioglitazone and metformin are inhibitors of formation of advanced glycation endproducts (age's)
US6573049B1 (en) 1999-07-26 2003-06-03 Nuvelo, Inc. Genotyping of the paraoxonase 1 gene for prognosing, diagnosing, and treating a disease
DE19936719A1 (de) * 1999-08-06 2001-02-15 Gruenenthal Gmbh Substituierte 1,5-Dihydropyrrol-2-on-Derivate
US6559188B1 (en) 1999-09-17 2003-05-06 Novartis Ag Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
AR030920A1 (es) 1999-11-16 2003-09-03 Smithkline Beecham Plc Composiciones farmaceuticas para el tratamiento de la diabetes mellitus y condiciones asociadas con la diabetes mellitus, y procedimientos para preparar dichas composiciones
US6680322B2 (en) 1999-12-02 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US6532467B1 (en) 2000-04-10 2003-03-11 Sas Institute Inc. Method for selecting node variables in a binary decision tree structure
US6432985B2 (en) 2000-04-25 2002-08-13 Hoffmann-La Roche Inc. Neuroprotective substituted piperidine compounds with activity as NMDA NR2B subtype selective antagonists
US20040122091A1 (en) * 2000-10-11 2004-06-24 Esperion Therapeutics, Inc. Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses
WO2002030884A2 (en) 2000-10-11 2002-04-18 Esperion Therapeutics, Inc. Sulfide and disulfide compounds and compositions for cholesterol management and related uses
US7304093B2 (en) * 2000-10-11 2007-12-04 Esperion Therapeutics, Inc. Ketone compounds and compositions for cholesterol management and related uses
CN1479721A (zh) * 2000-10-11 2004-03-03 ͨ��ҽ�ƹ�˾ 用于胆固醇治疗和相关应用的亚砜和双亚砜化合物和组合物
MXPA03003020A (es) * 2000-10-11 2003-07-14 Esperion Therapeutics Inc Compuestos de cetona y composiciones para el control del colesterol y usos relacionados.
US6838452B2 (en) 2000-11-24 2005-01-04 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
JP4162486B2 (ja) 2000-11-24 2008-10-08 ヴァスキュラー バイオジェニックス リミテッド アテローム性動脈硬化を防止および処置するための規定された酸化型リン脂質を用いる方法およびそのような酸化型リン脂質を含有する組成物
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US6495335B2 (en) 2000-12-07 2002-12-17 Mario Chojkier Compositions and methods for diagnosing alzheimer's disease
DE10132725A1 (de) 2001-07-05 2006-08-03 Grünenthal GmbH Substituierte γ-Lactonverbindungen
US6680299B2 (en) 2001-07-27 2004-01-20 Enanta Pharmaceuticals, Inc. 4'-substituted leucomycins
US20040204502A1 (en) * 2001-10-11 2004-10-14 Dasseux Jean-Louis Henri Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses
US20050020694A1 (en) 2001-10-11 2005-01-27 Dasseux Jean-Louis Henri Sulfide and disulfide compounds and compositions for cholesterol management and related uses
US6828462B2 (en) 2001-11-07 2004-12-07 Merz Pharma Gmbh & Co. Kgaa Unsaturated 1-amino-alkylcyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists
US7132244B2 (en) * 2001-11-21 2006-11-07 Syn X Pharma, Inc. Betaine/GABA transport protein biopolymer marker indicative of insulin resistance
US7135297B2 (en) 2001-11-23 2006-11-14 Nanogen Inc. Protein biopolymer markers indicative of insulin resistance
US7052849B2 (en) 2001-11-23 2006-05-30 Syn X Pharma, Inc. Protein biopolymer markers predictive of insulin resistance
US20030220374A1 (en) * 2002-01-14 2003-11-27 Pharmacia Corporation Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors
WO2004005510A1 (ja) 2002-07-05 2004-01-15 Shionogi & Co., Ltd. 新規Nogo受容体様ポリペプチドおよびそのＤＮＡ
US20040265849A1 (en) * 2002-11-22 2004-12-30 Applera Corporation Genetic polymorphisms associated with Alzheimer's disease, methods of detection and uses thereof
CN1753662A (zh) * 2002-12-24 2006-03-29 神经化学（国际）有限公司 用于治疗β－淀粉状蛋白相关疾病的治疗制剂
JP2006519440A (ja) * 2003-02-14 2006-08-24 インタージェネティックス インコーポレイテッド 疾患の増大リスクの統計学的同定法
US7141669B2 (en) 2003-04-23 2006-11-28 Pfizer Inc. Cannabiniod receptor ligands and uses thereof
US20050004179A1 (en) * 2003-05-22 2005-01-06 Pedersen Ward A. Methods and materials for treating, detecting, and reducing the risk of developing Alzheimer's Disease
US20070203083A1 (en) 2003-06-13 2007-08-30 Mootha Vamsi K Methods Of Regulating Metabolism And Mitochondrial Function
TW200520745A (en) 2003-09-19 2005-07-01 Chugai Pharmaceutical Co Ltd Novel 4-phenylamino-benzaldoxime derivatives and uses thereof as mitogen-activated protein kinase kinase (MEK) inhibitors
JP2007526764A (ja) 2004-01-22 2007-09-20 ジェネッサンス ファーマシューティカルズ，インコーポレイティド アルツハイマー病の発症年齢に関連するａｐｏｅ遺伝子マーカー
TW200538738A (en) 2004-02-20 2005-12-01 Univ California Molecular flux rates through critical pathways measured by stable isotope labeling in vivo, as biomarkers of drug action and disease activity
WO2006054297A2 (en) 2004-11-17 2006-05-26 Compugen Ltd. Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
WO2006083854A2 (en) 2005-01-31 2006-08-10 Perlegen Sciences, Inc. Genetic basis of alzheimer's disease and diagnosis and treatment thereof
EP2275095A3 (en) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
BRPI0616100A2 (pt) 2005-09-22 2011-06-07 Sb Pharmco Inc combinação de rosiglitazona e donepezil para melhoramento da função cognitiva
WO2007044522A1 (en) 2005-10-05 2007-04-19 Auburn University P62 as a risk determinant for metabolic syndrome
UA96441C2 (ru) 2006-03-16 2011-11-10 Метаболик Солюшнз Девелопмент Компани Фармацевтическая композиция, которая содержит аналог тиазолидиндиона митоглитазон, для лечения заболеваний, опосредованных метаболическим воспалением
US20080045582A1 (en) 2006-05-15 2008-02-21 Issam Zineh ENA-78 Gene Polymorphisms and Protein Concentrations as Diagnostic and Prognostic Tools
US8486635B2 (en) 2006-05-30 2013-07-16 Mayo Foundation For Medical Education And Research Detecting and treating dementia
US7651840B2 (en) * 2006-07-14 2010-01-26 Celera Corporation Genetic polymorphisms associated with Alzheimer's disease, methods of detection and uses thereof
US20080103165A1 (en) 2006-09-19 2008-05-01 Braincells, Inc. Ppar mediated modulation of neurogenesis
US20090042849A1 (en) 2006-12-06 2009-02-12 Yochai Birnbaum Phosphorylation of 5-lipoxygenase at ser523 and uses thereof
US7794937B2 (en) 2006-12-22 2010-09-14 Quest Diagnostics Investments Incorporated Cystic fibrosis transmembrane conductance regulator gene mutations
GB0702537D0 (en) 2007-02-12 2007-03-21 Leuven K U Res & Dev Treatment for excessive adiposity
US20080286876A1 (en) 2007-05-14 2008-11-20 Chissoe Stephanie GENES ASSOCIATED WITH ALZHEIMER'S DISEASE - Hltdip
CA2688293A1 (en) 2007-05-25 2008-12-04 Childrens's Medical Center Corporation Dietary formulations and methods for treatment of inflammation and other disorders
TW200914006A (en) 2007-07-12 2009-04-01 Takeda Pharmaceutical Coated preparation
US8846315B2 (en) * 2008-08-12 2014-09-30 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
EA021399B1 (ru) 2008-08-12 2015-06-30 Зинфандел Фармасьютикалз, Инк. Способ идентификации факторов риска заболеваний
US20100136584A1 (en) 2008-09-22 2010-06-03 Icb International, Inc. Methods for using antibodies and analogs thereof
WO2010033913A1 (en) 2008-09-22 2010-03-25 Icb International, Inc. Antibodies, analogs and uses thereof
BRPI0919882A8 (pt) 2008-10-30 2017-09-19 Caris Life Sciences Luxembourg Holdings Métodos para avaliar padrões de rna
WO2010056337A2 (en) 2008-11-12 2010-05-20 Caris Mpi, Inc. Methods and systems of using exosomes for determining phenotypes
EP2367802B1 (en) 2008-12-12 2016-04-20 Poxel Tetrahydrotriazine compounds for treating diseases associated with ampk activity
CA2751227C (en) 2009-02-02 2021-10-26 Laila Nutraceuticals Composition from sphaeranthus indicus and garcinia mangostana for the control of metabolic syndrome
US8865648B2 (en) 2009-04-23 2014-10-21 Siemens Healthcare Diagnostics Inc. Monomeric and dimeric forms of adiponectin receptor fragments and methods of use
AU2010202926B2 (en) 2009-09-11 2016-07-14 Electrophoretics Limited Markers and methods relating to the assessment of Alzheimer's disease
US8574856B2 (en) 2010-02-10 2013-11-05 Companion Diagnostics Inc. Methods for determining the efficiency of a therapeutic
AU2011223789A1 (en) 2010-03-01 2012-09-20 Caris Life Sciences Switzerland Holdings Gmbh Biomarkers for theranostics
CA2795776A1 (en) 2010-04-06 2011-10-13 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Circulating biomarkers for disease
KR20180050420A (ko) * 2011-01-10 2018-05-14 진판델 파마슈티컬스 인코포레이티드 알츠하이머 병 치료를 위한 방법 및 약품

Similar Documents

Publication Publication Date Title
JP2012500004A5 (ja)
JP2014528474A5 (ja)
EA201891154A1 (ru) Ингибиторы рециклинга желчных кислот при лечении холестатических заболеваний печени у детей
JP2011511805A5 (ja)
WO2008064299A3 (en) Methods of reducing porcine circovirus-associated disease outbreaks
JP2014506321A5 (ja)
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
MX2014004548A (es) Metodos para tratar pacientes pediatricos usando dexmedetomidina.
WO2010062688A3 (en) Dosage form for insertion into the mouth
JP2013537891A5 (ja)
GB2496794A (en) Combination pharmaceutical composition and methods of treating and methods of treating functional diseases or conditions of gastrointestinal tract
JP2010535767A5 (ja)
JP2013510169A5 (ja)
JP2014513722A5 (ja)
BR112014009910A2 (pt) formulações de sal de meglumina de ácido 1-(5,6-dicloro-1h-benzo[d]imidazol-2-il)-1h-pirazol-4-carboxílico
JP2012525346A5 (ja)
JP2011046708A5 (ja)
JP2013541583A5 (ja)
JP2009541409A5 (ja)
FI2683245T4 (fi) Menetelmiä ja koostumuksia masennuksen hoitamiseen syklobentsapriiniä käyttämällä
JP2011519873A5 (ja)
JP2016531853A5 (ja)
JP2017061488A5 (ja)
JP2016521754A5 (ja)
JP2013502449A5 (ja)